TITLE

Human embryonic stem cell transplantation to repair the infarcted myocardium

AUTHOR(S)
Leor, Jonathan; Gerecht, Sharon; Cohen, Smadar; Miller, Liron; Holbova, Radka; Ziskind, Anna; Shachar, Michal; Feinberg, Micha S.; Guetta, Esther; Itskovitz-Eldor, Joseph
PUB. DATE
October 2007
SOURCE
Heart;Oct2007, Vol. 93 Issue 10, p1278
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
9Objective: To test the hypothesis that human embryonic stem cells (hESCs) can be guided to form new myocardium by transplantation into the normal or infarcted heart, and to assess the influence of hESC-derived cardiomyocytes (hESCMs) on cardiac function in a rat model of myocardial infarction (MI). Methods: Undifferentiated hESCs (0.5-1 × 106), human embryoid bodies (hEBs) (4-8 days; 0.5-1 × 106), 0.1 mm pieces of embryonic stem-derived beating myocardial tissue, and phosphate-buffered saline (control) were injected into the normal or infarcted myocardium of athymic nude rats (n = 58) by direct injection into the muscle or into preimplanted three-dimensional alginate scaffold. By 2-4 weeks after transplantation, heart sections were examined to detect the human cells and differentiation with fluorescent in situ hybridisation, using DNA probes specific for human sex chromosomes and HLA-DR or HLA-ABC immunostaining. Results: Microscopic examination showed transplanted human cells in the normal, and to a lesser extent in the infarcted myocardium (7⁄7 vs 2⁄6; p<0.05). The transplanted hESCs and hEBs rarely created new vessels and did not form new myocardium. Transplantation of hESCM tissue into normal heart produced islands of disorganised myofibres, fibrosis and, in a single case, a teratoma. However, transplantation of hESCMs into the infarcted myocardium did prevent post-MI dysfunction and scar thinning. Conclusions: Undifferentiated hESCs and hEBs are not directed to form new myocardium after transplantation into normal or infarcted heart and may create teratoma. Nevertheless, this study shows that hESC-derived cardiomyocyte transplantation can attenuate post-MI scar thinning and left ventricular dysfunction.
ACCESSION #
27096316

 

Related Articles

  • Human embryonic stem cells for cardiac repair: the focus is on refined selection and cardiopoietic programming. Janssens, Stefan // Heart;Oct2007, Vol. 93 Issue 10, p1173 

    The author reflects on the article "Human Embryonic Stem Cell (HESC) Transplantation to Repair the Infarcted Myocardium," by Jonathan Leor and colleagues. He stresses that the authors' major importance of the findings is the need for proper cardiac specification before transplanting HES cells or...

  • Autologous bone marrow cell transplantation combined with off-pump coronary artery bypass grafting in patients with ischemic cardiomyopathy. Kyung-Jong Yoo; Hyun-Ok Kim; Young-Lan Kwak; Seok-Min Kang; Yang-Soo Jang; Sang-Hyun Lim; Ki-Chul Hwang; Seung-Woo Cho; Yoon-Sun Yang; Ren-Ke Li; Byung-Soo Kim // Canadian Journal of Surgery;Aug2008, Vol. 51 Issue 4, p269 

    Background: Clinical studies have demonstrated that intracoronary or intramyocardial transplantation of bone marrow mononuclear cells (BMMNCs) into ischemic myocardium improves cardiac function. The objective of the present study was to evaluate the safety and feasibility of intramyocardial...

  • Human embryonic stem cells: towards therapies for cardiac disease. Derivation of a Dutch human embryonic stem cell line. van de Stolpe, Anja; van De Brink, Stieneke; van Rooijen, Marga; Ward-van Oostwaard, Dorien; van Inzen, Wouter; Slaper-Cortenbach, Ineke; Fauser, Bart; van den Hout, Nijske; Weima, Sjerp; Passier, Robert; Smith, Nigel; Dening, Chris; Mummery, Christine // Reproductive BioMedicine Online (Reproductive Healthcare Limited;Oct2005, Vol. 11 Issue 4, p476 

    Cell transplantation is being discussed as a potential therapy for multiple disorders caused by loss or malfunction of single or at most a few cell types. These include diabetes. Parkinson's disease and myocardial infarction or cardiac failure. However, it is not yet clear whether cells from...

  • Human Embryonic Stem Cell-Derived Cardiomyocytes for Heart Therapies. Chung Wah Siu; Moore, Jennifer C.; Li, Ronald A. // Cardiovascular & Haematological Disorders - Drug Targets;Jun2007, Vol. 7 Issue 2, p145 

    Cardiovascular diseases remain the leading cause of mortality and morbidity worldwide. Despite substantial improvements in acute management, survivors of myocardial infarction often progress to heart failure. Since adult cardiomyocytes (CMs) do not regenerate, their loss permanently compromises...

  • Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Laflamme, Michael A.; Chen, Kent Y.; Naumova, Anna V.; Muskheli, Veronica; Fugate, James A.; Dupras, Sarah K.; Reinecke, Hans; Chunhui Xu; Hassanipour, Mohammad; Police, Shailaja; O'Sullivan, Chris; Collins, Lila; Yinhong Chen; Minami, Elina; Gill, Edward A.; Ueno, Shuichi; Chun Yuan; Gold, Joseph; Murry, Charles E. // Nature Biotechnology;Sep2007, Vol. 25 Issue 9, p1015 

    Cardiomyocytes derived from human embryonic stem (hES) cells potentially offer large numbers of cells to facilitate repair of the infarcted heart. However, this approach has been limited by inefficient differentiation of hES cells into cardiomyocytes, insufficient purity of cardiomyocyte...

  • Shortcuts to making cardiomyocytes. Huansheng Xu; Yi, B. Alexander; Chien, Kenneth R. // Nature Cell Biology;Mar2011, Vol. 13 Issue 3, p191 

    The adult human heart lacks sufficient regenerative capacity to recover after a myocardial infarction. Cell-based therapy has emerged as a potential treatment for the failing heart; however, a key issue for the success of future cell-based therapies is the ability to obtain patient-specific...

  • Stem Cells: Properties and Prospective Medical Applications. Musina, R. A.; Yegorov, Ye. Ye.; Belyavsky, A. V. // Molecular Biology;Jul/Aug2004, Vol. 38 Issue 4, p469 

    The properties of some stem cells (SCs) that are most interesting in terms of their implications for medicine (embryonic, hematopoietic, and mesenchymal SCs) are considered. SCs are undifferentiated cells capable of both self-maintenance and differentiation into specialized cells. According to...

  • Autologous bone marrow cell transplantation improves left ventricular function in rabbit hearts with cardiomyopathy via myocardial regeneration-unrelated mechanisms. Chuanjiang Lu; Arai, Masazumi; Misao, Yu; Xuehai Chen; Ningyuan Wang; Onogi, Hirohito; Kobayashi, Hiroyuki; Uno, Yoshihiro; Takemura, Genzou; Minatoguchi, Shinya; Fujiwara, Takako; Fujiwara, Hisayoshi // Heart & Vessels;May2006, Vol. 21 Issue 3, p180 

    Recent studies suggest transplanted bone marrow cells (BMCs) can be used to reconstitute coronary vessels and myocardium following acute myocardial infarction, thereby improving cardiac function. We sought to investigate the therapeutic potential of BMC transplantation in the treatment of...

  • Strategies for directing the differentiation of stem cells into the cardiomyogenic lineage in vitro. Heng, Boon Chin; Haider, Husnain Kh; Sim, Eugene Kwang-Wei; Cao, Tong; Ng, Soon Chye // Cardiovascular Research;Apr2004, Vol. 62 Issue 1, p34 

    Most studies on stem cell transplantation therapy on myocardially infarcted animal models and phase-I human clinical trials have focused on the use of undifferentiated stem cells. There is a strong possibility that some degree of cardiomyogenic differentiation of stem cells in vitro prior to...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics